Literature DB >> 10823843

Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.

M A Accola1, B Strack, H G Göttlinger.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) Gag precursor Pr55(gag) by itself is capable of assembling into retrovirus-like particles (VLP). In the present study, we attempted to identify the minimal Gag sequences required for the formation of VLP. Our results show that about 80% of Pr55(gag) can be either deleted or replaced by heterologous sequences without significantly compromising VLP production. The smallest chimeric molecule still able to efficiently form VLP was only about 16 kDa. This minimal Gag construct contained the leucine zipper domain of the yeast transcription factor GCN4 to substitute for the assembly function of nucleocapsid (NC), followed by a P-P-P-P-Y motif to provide late budding (L) domain function, and retained only the myristylation signal and the C-terminal capsid-p2 domain of Pr55(gag). We also show that the L domain function of HIV-1 p6(gag) is not dependent on the presence of an active viral protease and that the NC domain of Pr55(gag) is dispensable for the incorporation of Vpr into VLP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823843      PMCID: PMC112023          DOI: 10.1128/jvi.74.12.5395-5402.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  Recent advances and remaining problems in HIV assembly.

Authors:  L Garnier; J B Bowzard; J W Wills
Journal:  AIDS       Date:  1998       Impact factor: 4.177

Review 2.  HIV-1 gag proteins: diverse functions in the virus life cycle.

Authors:  E O Freed
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

3.  The role of nucleocapsid of HIV-1 in virus assembly.

Authors:  L Dawson; X F Yu
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

4.  Particle size determinants in the human immunodeficiency virus type 1 Gag protein.

Authors:  L Garnier; L Ratner; B Rovinski; S X Cao; J W Wills
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

5.  N-Terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles.

Authors:  I Gross; H Hohenberg; C Huckhagel; H G Kräusslich
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants.

Authors:  P B Harbury; T Zhang; P S Kim; T Alber
Journal:  Science       Date:  1993-11-26       Impact factor: 47.728

7.  Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release.

Authors:  C T Wang; H Y Lai; J J Li
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  Mutational analysis of the hydrophobic tail of the human immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails to package its envelope protein.

Authors:  D E Ott; E N Chertova; L K Busch; L V Coren; T D Gagliardi; D G Johnson
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly.

Authors:  A Borsetti; A Ohagen; H G Göttlinger
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids.

Authors:  W Zhou; L J Parent; J W Wills; M D Resh
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  176 in total

Review 1.  Ubiquitin in retrovirus assembly: actor or bystander?

Authors:  V M Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions.

Authors:  J B Bowzard; J W Wills; R C Craven
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Nucleic acid-independent retrovirus assembly can be driven by dimerization.

Authors:  Marc C Johnson; Heather M Scobie; Yu May Ma; Volker M Vogt
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  RNA incorporation is critical for retroviral particle integrity after cell membrane assembly of Gag complexes.

Authors:  Shainn-Wei Wang; Anna Aldovini
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

7.  Nucleocapsid-RNA interactions are essential to structural stability but not to assembly of retroviruses.

Authors:  Shainn-Wei Wang; Kristin Noonan; Anna Aldovini
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Kinetic analysis of the role of intersubunit interactions in human immunodeficiency virus type 1 capsid protein assembly in vitro.

Authors:  Jason Lanman; Jennifer Sexton; Michael Sakalian; Peter E Prevelige
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Direct measurement of Gag-Gag interaction during retrovirus assembly with FRET and fluorescence correlation spectroscopy.

Authors:  Daniel R Larson; Yu May Ma; Volker M Vogt; Watt W Webb
Journal:  J Cell Biol       Date:  2003-09-29       Impact factor: 10.539

10.  Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras: implications for retrovirus assembly.

Authors:  Rachael M Crist; Siddhartha A K Datta; Andrew G Stephen; Ferri Soheilian; Jane Mirro; Robert J Fisher; Kunio Nagashima; Alan Rein
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.